Category Archives: Tms

Lepine JP, Briley M. The increasing burden of depression. Neuropsychiatr Dis Treat. 2011;7(Suppl 1):37.

PubMed PubMed Central Google Scholar

Miller S, DellOsso B, Ketter TA. The prevalence and burden of bipolar depression. J Affect Disord. 2014;169S1:S311.

Article Google Scholar

Diseases GBD, Injuries C. Global burden of 369 diseases and injuries in 204 countries and territories, 19902019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):120422.

Article Google Scholar

Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, Olesen J, Allgulander C, Alonso J, Faravelli C, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(9):65579.

Article CAS PubMed Google Scholar

Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jonsson B. group Cs, European Brain C: the economic cost of brain disorders in Europe. Eur J Neurol. 2012;19(1):15562.

Article CAS PubMed Google Scholar

Sinyor M, Schaffer A, Levitt A. The sequenced treatment alternatives to relieve depression (STAR*D) trial: a review. Can J Psychiatry. 2010;55(3):12635.

Article PubMed Google Scholar

Semkovska M, Quinlivan L, OGrady T, Johnson R, Collins A, OConnor J, Knittle H, Ahern E, Gload T. Cognitive function following a major depressive episode: a systematic review and meta-analysis. Lancet Psychiatry. 2019;6(10):85161.

Article PubMed Google Scholar

Hasselbalch BJ, Knorr U, Kessing LV. Cognitive impairment in the remitted state of unipolar depressive disorder: a systematic review. J Affect Disord. 2011;134(13):2031.

Article PubMed Google Scholar

Hammar , Ardal G. Cognitive functioning in major depressiona summary. Front Hum Neurosci. 2009;3:26.

Article PubMed PubMed Central Google Scholar

Allott K, Fisher CA, Amminger GP, Goodall J, Hetrick S. Characterizing neurocognitive impairment in young people with major depression: state, trait, or scar? Brain Behav. 2016;6(10):e00527.

Article PubMed PubMed Central Google Scholar

Hammar , Ronold EH, Rekkedal GA. Cognitive impairment and neurocognitive profiles in major depression-a clinical perspective. Front Psychiatry. 2022;13:764374.

Article PubMed PubMed Central Google Scholar

Gorwood P, Corruble E, Falissard B, Goodwin GM. Toxic effects of depression on brain function: impairment of delayed recall and the cumulative length of depressive disorder in a large sample of depressed outpatients. Am J Psychiatry. 2008;165(6):7319.

Article PubMed Google Scholar

Moylan S, Maes M, Wray NR, Berk M. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry. 2013;18(5):595606.

Article CAS PubMed Google Scholar

Carney S, Cowen P, Dearness K, Eastaugh J. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet. 2003;361(9360):799808.

Article Google Scholar

Schoeyen HK, Kessler U, Andreassen OA, Auestad BH, Bergsholm P, Malt UF, Morken G, Oedegaard KJ, Vaaler A. Treatment-resistant bipolar depression: a randomized controlled trial of electroconvulsive therapy versus algorithm-based pharmacological treatment. Am J Psychiatry. 2015;172(1):4151.

Article PubMed Google Scholar

Voineskos D, Daskalakis ZJ, Blumberger DM. Management of treatment-resistant depression: challenges and strategies. Neuropsychiatr Dis Treat. 2020;16:22134.

Article CAS PubMed PubMed Central Google Scholar

Aoki Y, Yamaguchi S, Ando S, Sasaki N, Bernick PJ, Akiyama T. The experience of electroconvulsive therapy and its impact on associated stigma: a meta-analysis. Int J Soc Psychiatry. 2016;62(8):70818.

Article PubMed Google Scholar

Read J, Cunliffe S, Jauhar S, McLoughlin DM. Should we stop using electroconvulsive therapy? BMJ. 2019;364:k5233.

Article PubMed Google Scholar

Peterchev AV, Rosa MA, Deng ZD, Prudic J, Lisanby SH. Electroconvulsive therapy stimulus parameters: rethinking dosage. J ECT. 2010;26(3):15974.

Article PubMed PubMed Central Google Scholar

Leiknes KA, Jarosh-von Schweder L, Hoie B. Contemporary use and practice of electroconvulsive therapy worldwide. Brain Behav. 2012;2(3):283344.

Article PubMed PubMed Central Google Scholar

Fraser LM, OCarroll RE, Ebmeier KP. The effect of electroconvulsive therapy on autobiographical memory: a systematic review. J ECT. 2008;24(1):107.

Article PubMed Google Scholar

Sackeim HA, Ross FR, Hopkins N, Calev L, Devanand DP. Subjective side effects acutely following ECT: associations with treatment modality and clinical response. Convuls Ther. 1987;3(2):10010.

PubMed Google Scholar

Semkovska M, Knittle H, Leahy J, Rasmussen JR. Subjective cognitive complaints and subjective cognition following electroconvulsive therapy for depression: a systematic review and meta-analysis. Aust N Z J Psychiatry. 2023;57(1):2133.

Landry M, Moreno A, Patry S, Potvin S, Lemasson M. Current practices of electroconvulsive therapy in mental disorders: a systematic review and meta-analysis of short and long-term cognitive effects. J ECT. 2021;37(2):11927.

Article PubMed Google Scholar

Semkovska M, McLoughlin DM. Objective cognitive performance associated with electroconvulsive therapy for depression: a systematic review and meta-analysis. Biol Psychiatry. 2010;68(6):56877.

Article PubMed Google Scholar

Kessler U, Schoeyen HK, Andreassen OA, Eide GE, Malt UF, Oedegaard KJ, Morken G, Sundet K, Vaaler AE. The effect of electroconvulsive therapy on neurocognitive function in treatment-resistant bipolar disorder depression. J Clin Psychiatry. 2014;75(11):e13061313.

Article PubMed Google Scholar

Kirov GG, Owen L, Ballard H, Leighton A, Hannigan K, Llewellyn D, Escott-Price V, Atkins M. Evaluation of cumulative cognitive deficits from electroconvulsive therapy. Br J Psychiatry. 2016;208(3):26670.

Article PubMed Google Scholar

Semkovska M, McLoughlin DM. Measuring retrograde autobiographical amnesia following electroconvulsive therapy: historical perspective and current issues. J ECT. 2013;29(2):12733.

Article PubMed Google Scholar

Rasmussen KG. What type of cognitive testing should be part of routine electroconvulsive therapy practice? J ECT. 2016;32(1):712.

Article PubMed Google Scholar

Ousdal OT, Brancati GE, Kessler U, Erchinger V, Dale AM, Abbott C, Oltedal L. The neurobiological effects of electroconvulsive therapy studied through magnetic resonance: what have we learned, and where do we go? Biol Psychiatry. 2022;91(6):5409.

Article PubMed Google Scholar

Nordanskog P, Larsson MR, Larsson EM, Johanson A. Hippocampal volume in relation to clinical and cognitive outcome after electroconvulsive therapy in depression. Acta Psychiatr Scand. 2014;129(4):30311.

Article CAS PubMed Google Scholar

Oltedal L, Narr KL, Abbott C, Anand A, Argyelan M, Bartsch H, Dannlowski U, Dols A, van Eijndhoven P, Emsell L, et al. Volume of the human hippocampus and clinical response following electroconvulsive therapy. Biol Psychiatry. 2018;84(8):57481.

Article PubMed PubMed Central Google Scholar

Argyelan M, Oltedal L, Deng Z-D, Wade B, Bikson M, Joanlanne A, Sanghani S, Bartsch H, Cano M, Dale AM, et al. Electric field causes volumetric changes in the human brain. eLife. 2019;8:e49115.

Article CAS PubMed PubMed Central Google Scholar

Mulders PCR, Llera A, Beckmann CF, Vandenbulcke M, Stek M, Sienaert P, Redlich R, Petrides G, Oudega ML, Oltedal L, et al. Structural changes induced by electroconvulsive therapy are associated with clinical outcome. Brain Stimul. 2020;13(3):696704.

Article PubMed Google Scholar

Deng ZD, Argyelan M, Miller J, Quinn DK, Lloyd M, Jones TR, Upston J, Erhardt E, McClintock SM, Abbott CC. Electroconvulsive therapy, electric field, neuroplasticity, and clinical outcomes. Mol Psychiatry. 2022;27(3):167682.

Article CAS PubMed Google Scholar

van Oostrom I, van Eijndhoven P, Butterbrod E, van Beek MH, Janzing J, Donders R, Schene A, Tendolkar I. Decreased cognitive functioning after electroconvulsive therapy is related to increased hippocampal volume: exploring the role of brain plasticity. J ECT. 2018;34(2):11723.

Article PubMed Google Scholar

Laroy M, Bouckaert F, Vansteelandt K, Obbels J, Dols A, Emsell L, Stek M, Vandenbulcke M, Sienaert P. Association between hippocampal volume change and change in memory following electroconvulsive therapy in late-life depression. Acta Psychiatr Scand. 2019;140(5):43545.

Article CAS PubMed Google Scholar

Cowey A. The Ferrier Lecture 2004 what can transcranial magnetic stimulation tell us about how the brain works? Philos Trans R Soc Lond B Biol Sci. 2005;360(1458):1185205.

Article PubMed PubMed Central Google Scholar

Walsh V, Cowey A. Transcranial magnetic stimulation and cognitive neuroscience. Nat Rev Neurosci. 2000;1(1):739.

Article CAS PubMed Google Scholar

De Raedt R, Vanderhasselt MA, Baeken C. Neurostimulation as an intervention for treatment resistant depression: From research on mechanisms towards targeted neurocognitive strategies. Clin Psychol Rev. 2015;41:619.

Article PubMed Google Scholar

OReardon JP, Solvason HB, Janicak PG, Sampson S, Isenberg KE, Nahas Z, McDonald WM, Avery D, Fitzgerald PB, Loo C, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry. 2007;62(11):120816.

Article PubMed Google Scholar

George MS, Wassermann EM, Williams WA, Callahan A, Ketter TA, Basser P, Hallett M, Post RM. Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. NeuroReport. 1995;6(14):18536.

Article CAS PubMed Google Scholar

Iimori T, Nakajima S, Miyazaki T, Tarumi R, Ogyu K, Wada M, Tsugawa S, Masuda F, Daskalakis ZJ, Blumberger DM, et al. Effectiveness of the prefrontal repetitive transcranial magnetic stimulation on cognitive profiles in depression, schizophrenia, and Alzheimers disease: a systematic review. Prog Neuropsychopharmacol Biol Psychiatry. 2019;88:3140.

Article PubMed Google Scholar

McClintock SM, Reti IM, Carpenter LL, McDonald WM, Dubin M, Taylor SF, et al. Consensus Recommendations for the Clinical Application of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Depression. J Clin Psychiatry. 2018;79(1):3548.

Lefaucheur JP, Aleman A, Baeken C, Benninger DH, Brunelin J, Di Lazzaro V, Filipovic SR, Grefkes C, Hasan A, Hummel FC, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (20142018). Clin Neurophysiol. 2020;131(2):474528.

Article PubMed Google Scholar

Baeken C, Brem AK, Arns M, Brunoni AR, Filipcic I, Ganho-Avila A, Langguth B, Padberg F, Poulet E, Rachid F, et al. Repetitive transcranial magnetic stimulation treatment for depressive disorders: current knowledge and future directions. Curr Opin Psychiatry. 2019;32(5):40915.

Article PubMed PubMed Central Google Scholar

Montgomery SA, sberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):3829.

Article CAS PubMed Google Scholar

Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An Inventory for Measuring Depression. Arch Gen Psychiatry. 1961;4(6):56171.

Article CAS PubMed Google Scholar

Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont (Pa: Township)). 2007;4(7):2837.

Google Scholar

Sunderland A, Harris JE, Baddeley AD. Do laboratory tests predict everyday memory? A neuropsychological study. J Verbal Learn Verbal Behav. 1983;22(3):34157.

Article Google Scholar

Strobel C, Engedal K. Norsk revidert mini mental status evaluering (MMSE-N3). Aldring og helse. 2018.

Google Scholar

Read the original here:

Neurobiological mechanisms of ECT and TMS treatment in ... - BMC Psychiatry

CHICAGO

Mishimoto, the global leader in performance cooling products for automotive enthusiasts, faced a critical challenge when a sudden provider change jeopardized their client deliveries. To overcome this disruption, Mishimoto turned toRedwood Logistics(Redwood), one of the fastest growing modern 4PL providers in North America, for a solution that would ensure continuity in their operations.

Founded in 2005, Mishimoto has been providing cooling system upgrades for a wide range of applications, including sport compacts, powersports, trucks, Jeeps, muscle vehicles, daily drivers and classic cars. When faced with the sudden provider change, the company sought to establish new rates, set up a rating and execution platform, support both full truckload (FTL) and less-than-truckload (LTL) shipments, and train and launch operations at two locations. Furthermore, the implementation of a transportation management system (TMS) was required to manage these complex logistics operations efficiently.

Redwood was selected to overcome this challenge as the company displayed remarkable agility and expertise. In less than two weeks, Redwood set up a TMS instance, provided essential pricing and training, and successfully launched operations at two locations. This rapid-fire implementation ensured that Mishimoto experienced no disruptions in client deliveries during this critical period.

Marc Barrer, Vice President of Operations at Mishimoto, said, Redwood's swift and reliable solutions enabled us to overcome a challenging situation with a sudden break in a provider relationship and continue our deliveries without any disruption. Their exceptional support, including TMS implementation and LTL and parcel management, has resulted in significant cost savings and positioned Mishimoto for continued success in our global market.

In addition to averting any client disruptions, Redwood Logistics provided a comprehensive solution that set Mishimoto up for long-term success. This included not only LTL management but also parcel procurement optimization through Redwoods carrier contract assessment and mediation service, resulting in substantial cost savings. Key Results Include:

Redwood continues to be a trusted partner for companies in the automotive aftermarket and performance cooling products industry, providing innovative solutions to streamline supply chain operations and reduce costs, said Mike Reed, Chief Product Officer, Redwood. As a modern 4PL solution we were best positioned to offer tailored and customized physical and digital supply chain solutions to help Mishimoto overcome their provider disruption.

To read the complete case study,follow the link here.

###

For more information, visit redwoodlogistics.com

See the original post here:

Mishimoto Partners with Redwood Logistics for Seamless TMS ... - Supply Chain Dive

Both a warehouse management system and a transportation management system can help companies with critical warehouse operations and integrating them can benefit organizations even further.

Integrating a TMS and WMS improves visibility into warehouse processes and can help improve scheduling. Supply chain leaders should also keep in mind that integrating a TMS and WMS is not always possible, depending on the systems.

Learn more about WMSes and how integrating them with a TMS can help improve operations.

A WMS application manages warehouse inventory, including product status, inventory quality and inventory location.

The WMS also helps with picking and packing by providing workers with location and quantity data.

In some cases, WMSes offer mobile functionality so workers can access the system while using a forklift or moving around the warehouse floor.

Companies with a large amount of warehouse products that workers must load and unload into trailers or trucks often use a TMS platform.

A TMS helps support load and route scheduling as well as compliance documentation and provides real-time visibility into product locations.

Using WMS and TMS separately can be challenging for warehouse workers, so integrating a WMS and TMS can improve daily operations.

Here are some other benefits of integrating the two systems.

Integrating a WMS and TMS reduces the need for data entry because workers won't have to manually key in load information into the TMS. The information will automatically transfer from the WMS to the TMS.

WMS-TMS integration also enables employees to track the status of each load and share the information with customers and internal staff if needed without having to switch between systems.

For example, employees of a manufacturer with integrated TMS and WMS can find out if the materials and ingredients for a scheduled production order will arrive in time.

This visibility also enables warehouse workers to plan ahead for shipments.

TMS-WMS integration enables companies to optimize their resources by improving the scheduling of trucks, drivers and warehouse staff.

Since a TMS-WMS integration provides visibility into truck and driver availability, users can schedule warehouse workers more effectively.

However, supply chain leaders should keep in mind that not all WMS and TMS platforms can be integrated. During the software vendor selection process, purchasing team members should ask whether the vendor can support system integration.

See more here:

3 benefits of integrating WMS and TMS software - TechTarget

Trinium, the leading provider of Transportation Management System (TMS) solutions for drayage operations in North America, and the home of your dispatch operations, has joined forces with BlueCargo, the pioneers behind the Per Diem Fighter, designed to secure empty container returns, stop the per diem clock, audit per diem bills, and facilitate real-time or historical fee recovery. Today, they are thrilled to announce this partnership aimed at integrating and monitoring all container activities and movements in real-time, including late fees, bringing users of both platforms a comprehensive back-end operational solution.

Unlocking container management efficiency: solving the demurrage and detention cost challenge

Container drayage is all about maximizing resource utilization. It's essential to deploy every truck and driver in your fleet efficiently to minimize idle time, reduce costs, and boost productivity. This not only improves your bottom line but also promotes a more sustainable and environmentally responsible operation.

Detention and demurrage (D&D) charges are financial penalties imposed on containers that are held at terminals or facilities beyond their allotted free time. These charges can have significant consequences for container drayage operators and avoiding them may not always be in your control.

For instance, a recent survey of D&D tariffs at 65 global ports reveals that 11 are still higher than 2020 levels, with seven of them located in the US. Several factors contribute to this situation, including increasing energy and labor costs, rising land expenses, and port fees. Given these challenges, its unlikely US port charges will return to normal any time soon.

As our sector continues to grapple with the ripple effects of the pandemic and ongoing economic constraints, its clear that D&D charges have the potential to exert even more financial pressure on your business.

This is where technology plays a crucial role. By utilizing advanced software, you can expedite container movements, ensure timely pick-ups and drop-offs, and proactively manage your fleet, ultimately mitigating the impact of D&D charges on your financial performance.

How Trinium and BlueCargo are Empowering Smarter Container Management

With an extensive presence in every port and rail market across the United States and Canada, Trinium TMS is a comprehensive enterprise system purpose-built for modern container drayage and intermodal trucking companies.

We believe in providing our customers with best-in-breed technology solutions, which is why we are proud to partner with BlueCargo, the leading platform for detention and demurrage mitigation.

With the integration of BlueCargo's end-to-end dispute system into Triniums advanced TMS, you now have state-of-the-art per diem audit and dispute resolution tools at your fingertips.

Streamline per diem disputes

With BlueCargo's AI-powered technology, you can recover up to 75 percent of disputable per diem invoices, centralize disputes, and reduce invoice processing time by 95 percent. It efficiently identifies rule violations, automatically audits per diem charges for accurate savings calculations, and enables you to review potential invoice savings.

Additionally, the platform allows you to gather supporting evidence and submit documentation to the SSL for dispute initiation. You can easily track and manage all per diem disputes, following up on email threads with SSLs until resolutions are achieved.

Trinium TMS and BlueCargo a powerful combination

Today, we all rely on technology to streamline processes, improve productivity, and stay competitive. The ability to seamlessly integrate new tools and applications into our digital ecosystems is crucial to staying ahead.

However, closed operating systems can present significant limitations, hindering your ability to expand and optimize your container drayage capabilities. Thats why Trinium partners with leading drayage technology specialists, like BlueCargo, to create a powerful ecosystem of tools and resources that empower your teams to make data-driven decisions, reduce costs, and improve overall performance.

Continued here:

Trinium and BlueCargo join forces to increase resiliency and agility ... - American Journal of Transportation

BOSTON A Natick psychiatrist was convicted by a federal jury yesterday of billing Medicare and private insurance companies for over $11 million in treatments he did not provide and obstructing justice in an attempt to conceal his crimes.

Gustavo Kinrys, 52, of Wellesley, was convicted of seven counts of wire fraud, six counts of false statements relating to health care matters and one count of obstructing a criminal health care investigation. U.S. District Court Judge Denise J. Casper scheduled sentencing for Jan. 31, 2023. Kinrys was arrested and charged in December 2020.

Dr. Kinrys shamelessly billed for over $11 million in treatment from Medicare and private insurers treatments he never provided. He exploited our healthcare system and showed callous disregard for patient well-being, said Acting United States Attorney Joshua S. Levy. This conviction should send a stern message: healthcare fraud will not go unpunished, and those who exploit our vital healthcare system for personal gain will face the full extent of the law.

Through his scheme to defraud the Medicare program, the defendant stole taxpayer funds and violated the publics trust in his position as a physician, said Roberto Coviello, Special Agent in Charge of the U.S. Department of Health and Human Services, Office of Inspector General. This conviction sends a clear message that we will hold accountable those who exploit our federal health care system for personal gain, and we will not tolerate attempts to obstruct our pursuit of justice.

This conviction is a big win for taxpayers who were cheated when Dr. Kinrys fraudulently billed Medicare and private insurance companies for more than $11 million for medical treatments he never provided and then obstructed our investigation in an attempt to conceal his crimes, said Jodi Cohen, Special Agent in Charge of the FBI Boston Division. Healthcare fraud is not a victimless crime. It can raise health insurance premiums, expose patients to unnecessary medical procedures, and increase taxes. Anyone involved in, or entertaining similar activity, should know the FBI and our partners will not hesitate to pursue those trying to steal from our countrys vital health care system.

This matter illustrates the commitment of all agencies to combat medical billing fraud which affects all citizens. The Insurance Fraud Bureau of Massachusetts places a high priority on fighting this type of insurance fraud. Our continuing collaboration with our partners is critical to successfully fight insurance fraud, said Anthony M. DiPaolo, Executive Director of the Massachusetts Insurance Fraud Bureau.

Kinrys was a licensed psychiatrist who owned and operated Advanced TMS Associates, located in Natick, Mass. Among other services, Kinrys offered transcranial magnetic stimulation (TMS) therapy and psychotherapy to patients suffering from depression. TMS therapy is a noninvasive method of brain stimulation that uses rapidly alternating or pulsed magnetic fields to induce electrical currents directed at a patients cerebral cortex.

Between January 2015 and December 2018, Kinrys engaged in a variety of fraudulent billing schemes in which he sought and received reimbursement for services he did not render. For example, Kinrys billed Medicare and private insurers $10.6 million for thousands of TMS sessions he never provided, including over 8,000 sessions he claimed were provided to 74 patients who, in fact, never received a single session of the therapy. Kinrys billed Medicare and private insurers for hundreds of thousands of dollars worth of psychotherapy sessions he never provided, including over 900 face-to-face sessions he falsely claimed he provided while he was on vacation in locations like the Bahamas, Punta Cana, Dominican Republic, and the Czech Republic. On 382 occasions, Kinrys billed Medicare and private insurers for having provided more than 24 hours worth of psychotherapy services in a single day, including one day in July 2017 when he claimed he had provided hour-long psychotherapy sessions to 70 different patients all while outside the United States on vacation.

To further his fraudulent billing scheme, Kinrys made numerous false statements to his patients, the billing company with which he worked and the insurers to whom he submitted claims seeking reimbursement. When Medicare, private insurers and the Department of Health and Human Services (HHS) sought records from Kinrys pertaining to certain of his claims, he took steps to conceal his fraudulent conduct by making false representations and creating false documentation purporting to show that he had provided thousands of treatments he had billed for, but never rendered. For example, in response to a July 2018 subpoena from the HHSs Office of Inspector General seeking medical records for 10 of his patients, Kinrys created documents and ordered his office workers to create documents falsely stating that those patients had received dozens of treatments they had never been provided and falsely representing that the condition of those patients was improving. The wire fraud charges provide for a sentence of up to 20 years in prison, three years of supervised release and a fine of $250,000 or twice the gross gain or loss, whichever is greater. The charges of false statements relating to health care matters and obstruction of a criminal investigation of a health care offense each provide for a sentence of up to five years in prison, three years of supervised release and a fine of $250,000 or twice the gross gain or loss, whichever is greater. Sentences are imposed by a federal district court judge based upon the U.S. Sentencing Guidelines and statutes which govern the determination of a sentence in a criminal case.

Acting U.S. Attorney Levy, HHS-OIG SAC Coviello, FBI Boston SAC Cohen and MA IFB Director DiPaolo made the announcement today. Assistant U.S. Attorneys Patrick M. Callahan and Christopher R. Looney of the Health Care Fraud Unit are prosecuting the case.

See the original post:

Psychiatrist Convicted of Billing Medicare and Private Insurance ... - Department of Justice

We proudly recognize FreightPOP as an Acumatica-Certified Application that masterfully utilizes the Acumatica platform to enable customers to execute their strategies and meet their evolving business needs.

Acumatica is a comprehensive, browser-based cloud ERP solution optimized for ease of use, adaptability, mobility, speed, and security. The ACA title highlights only outstanding development partners whose applications have met specific standards of excellence.

"Customers looking to stay competitive need flexible, responsive technology and resilient systems to thrive and grow," said Christian Lindberg, vice president of partner solutions at Acumatica. "Our ACA label is designed to help customers find those applications that are most capable of delivering. We proudly recognize FreightPOP as an Acumatica-Certified Application that masterfully utilizes the Acumatica platform to enable customers to execute their strategies and meet their evolving business needs."

To become an Acumatica-Certified Application, FreightPOP has demonstrated commitment to quality by passing the Acumatica software test and aligning to future Acumatica roadmap releases.

"Through the seamless integration of FreightPOP and Acumatica, we're empowering businesses to elevate their logistics game," said Jon Freeman, Head of Partnerships at FreightPOP. "This partnership isn't just about connecting systems; it's about connecting opportunities for growth and efficiency in supply chain management."

About FreightPOP

FreightPOP, based in Lake Forest, CA, is a leading provider of transportation management and logistics software. The company offers a comprehensive platform that helps businesses streamline their supply chain operations, optimize shipping, and achieve cost savings. With a focus on user-friendly solutions and exceptional customer support, FreightPOP is trusted by companies of all sizes to improve their logistics processes. Learn more by visiting http://www.freightpop.com.

Media Contact

Holly Heitmann, FreightPOP, 1 9494544602, [emailprotected], http://www.freightpop.com

SOURCE FreightPOP

Original post:

FreightPOP TMS Application Earns Acumatica Certification - PR Web

Consultation and TMS Integration Support for Financial Institutions Led by

AML RightSource Financial Crime Advisory Group

CLEVELAND (October 26, 2023) AML RightSource, the leading provider of Anti-Money Laundering (AML), Know Your Customer (KYC), and Bank Secrecy Act (BSA) compliance solutions, has expanded its Financial Crimes Advisory (FCA) services to financial institutions with expert support for transaction monitoring system (TMS) selection and implementation. This new offering complements AML RightSources capabilities that help clients validate and optimize existing technology investments to improve compliance programs.

With an increasing number of financial institutions contemplating replacing or upgrading their TMS because of outdated technology or inadequate capabilities, AML RightSources FCA team offers unparalleled expertise to assist in both the selection and implementation of solutions that are optimal for each clients specific needs and compliance operation. End-to-end support provided by AML RightSource includes identifying client requirements, development of RFPs, consultation on the selection of TMS vendors, vendor correspondence, contract negotiation, and leading the implementation process.

Focused solely on the challenges of financial crime compliance, AML RightSource offers consulting services, advanced technology, and boasts 4,000 employees working every day with AML compliance teams around the world. This concentration and scale give AML RightSource unique insights into how compliance teams can optimize their TMS and how transaction monitoring is evolving to deliver greater performance.

When selecting and implementing a new TMS, the AML RightSource FCA team works with clients to:

Most compliance leaders may handle a TMS change only once in their career. A successful compliance software switch is possible with careful planning and a knowledgeable team. AML RightSource has done this many times and is there to guide clients from start to finish, explained Chuck Taylor, Executive VP, Head of Financial Crimes Advisory at AML RightSource. With an implementation support partner like AML RightSource, clients get years of dedicated subject matter expertise, established vendor relationships, and in-depth technical knowledge. This helps bridge the gap between business goals and vendor requirements, ultimately leading to successful implementations.

About AML RightSource, LLC

AML RightSource is the leading technology-enabled managed services firm focused on fighting financial crime for our clients and the world. AML RightSource provides custom solutions to financial institutions, FinTechs, money service businesses, and corporations. Using a blend of highly trained anti-financial crime professionals, cutting-edge technology tools, and industry-leading consultants, AML RightSource assists clients with their AML/BSA, transaction monitoring, client onboarding (KYC), enhanced due diligence (EDD), and risk management needs. We support clients in meeting day-to-day compliance tasks, urgent projects, and strategic changes. Our global staff of more than 4,000 highly trained analysts and subject matter experts is the industrys largest group of full-time compliance professionals. AML RightSource is headquartered in Cleveland, Ohio. With our clients around the world, we are Reimagining Compliance. For more information, visit http://www.amlrightsource.com.

Go here to see the original:

AML RightSource Offers Support for Transaction Monitoring System Selection and Integration - Global Banking And Finance Review

At 25, Sierra Johnson feels good about working a full-time job, setting goals for herself, and looking forward to the future.

However, this wasnt always the case.

Just a few months ago, Sierra wouldnt leave her bedroom, let alone her house. She loved working with children but couldnt keep her job at a day care center.

Since she was a young teenager, Sierras anxiety and depression symptoms interfered with school, work, relationships, and life in general. So much so, she shut out the world and hid behind room-darkening curtains in her bedroom.

I was going down this path from fifth grade until now that I was just never happy, Sierra said. I gave up on everything. I became angry and paranoid, and did not get along with my family.

I blamed everyone else, she said. I was stuck.

TMS therapy a game changer

Sierra heard about a treatment called transcranial magnetic stimulation, better known as TMS.

TMS is an outpatient therapy that uses a device to give very short pulses of magnetic energy to stimulate nerve cells in certain parts of the brain, explained Dr. Lindsay Campbell, WellSpan psychiatrist and behavioral health site director.

The magnetic device stimulates the underactive parts of the brain in patients diagnosed with depression.

Its quite effective for those patients experiencing major depressive disorder and anxious depression, Dr. Campbell said.

Once patients are referred for TMS, Tanya Seprinski, WellSpan TMS coordinator, works to arrange their treatment plan and sessions. She also works with insurance companies to get patients approved for the program.

The therapy is quick, with sessions lasting just 18 to 20 minutes. Its also safe, with minimal side effects, and patients can drive afterward. Typically, after a few weeks, patients notice a difference, Seprinski explained.

More than 500 patients have turned to WellSpan for TMS therapy. The program, which is available in York and Mt. Gretna, has the lowest drop-out rate in the country.

Our program has changed in that we have implemented several new devices and protocols which translate into less time in the TMS chair for patients and improved accuracy, Dr. Campbell said.

A new outlook on life

For Sierra, once she committed to TMS, there was no turning back. She completed all her treatments over a few months.

At first, the changes in Sierra were subtle.

After treatment 10, my attitude had really changed, she said. And that brought on other, larger changes. I was able to get out of bed and leave my room. I had more energy.

Sierra started noticing physical and emotional changes in herself. Next, family relationships began to heal, and she was back to taking her medication daily without skipping.

I was so happy, I cried, she said. The cloud hanging over me was gone and I could face the day with positivity.

Since completing TMS, Sierra is back to working full-time at her day care job and has the confidence to shop alone and mingle at large events, no longer feeling the need to hide in her bedroom.

She is sharing her story on social media and has been interviewed by reporters from local TV stations - all with the goal of promoting hope for others with depression and anxiety.

I will always have a diagnosis of anxiety and depression, but now I am able to deal with it, she said.

Results of TMS therapy

Studies have shown TMS can improve depression symptoms in up to 83% of patients undergoing treatment, and 62% of them achieve symptoms of relief or remission from their depression.

In addition to depression, the FDA has also approved TMS for obsessive-compulsive disorder, migraines, and smoking cessation, although these are separate protocols than the ones used for depression.

To learn more about TMS therapy, visit WellSpan Philhaven, here.

View original post here:

TMS therapy: The cloud hanging over me was gone - WellSpan Health